SCHEMBL7205123

SCHEMBL7205123

Cc1cc(Nc2ncc(Cc3ccncc3)c3ccccc23)ccc1C(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FLT1 P17948 15/20 0.44
▸ KDR P35968 15/20 0.44
▸ PDGFRB P09619 11/20 0.44
▸ KIT P10721 10/20 0.44
▸ CDK8 P49336 2/20 0.39
▸ CIT O14578 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ HLA-A P04439 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ RET P07949 1/20 0.39
▸ PDGFRA P16234 1/20 0.39
▸ RPS6KB1 P23443 1/20 0.39
▸ FLT4 P35916 1/20 0.39
▸ FRK P42685 1/20 0.39
▸ DDR1 Q08345 1/20 0.39
▸ STK3 Q13188 1/20 0.39
▸ PTK6 Q13882 1/20 0.39
▸ MAP3K19 Q56UN5 1/20 0.39
▸ CDK19 Q9BWU1 1/20 0.39
▸ MAP3K20 Q9NYL2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13955450 0.88 FLT1 (0.48) FLT1KDRPDGFRBKITCDK8
SCHEMBL13955594 0.86 KDR (0.51) FLT1KDRPDGFRBKITCDK8
SCHEMBL13955413 0.85 KDR (0.37) FLT1KDRPDGFRBKITSMN1; SMN2
SCHEMBL13955448 0.84 FLT1 (0.47) FLT1KDRPDGFRBKITCDK8
SCHEMBL13955571 0.83 KDR (0.48) FLT1KDRPDGFRBKITCDK8
SCHEMBL2203269 0.83 FLT1 (0.46) FLT1KDRPDGFRBKITCDK8
SCHEMBL13955412 0.83 KDR (0.48) FLT1KDRPDGFRBKITCDK8
SCHEMBL1383433 0.82 NAMPT (0.47) FLT1KDREGFRNAMPT
SCHEMBL13955587 0.82 FLT1 (0.46) FLT1KDRPDGFRBKITCDK8
SCHEMBL3152355 0.82 FLT1 (0.64) FLT1KDRPDGFRBKITCDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608071-B2 Angiogenesis inhibitors as antitumor agents NOVARTIS AG (CH) 2003-08-19 — — US claimed
EP-1603566-B1 USE OF ISOQUINOLINE DERIVATIVES FOR TREATING CANCER AND MAP KINASE RELATED DISEASES NOVARTIS AG (CH) 2009-01-21 — — EP disclosed
Send feedback